Objective We previously demonstrated that short-term treatment with a standardized kudzu extract (NPI-031) reduced alcohol drinking by men and women in a natural setting. The present study was conducted in nontreatment-seeking heavy drinkers to assess the safety and efficacy of 4 weeks of kudzu extract in an outpatient setting. Method This randomized between-subject, double-blind, placebo-controlled study involved 2 weeks of baseline, 4 weeks of treatment, and 2 weeks of follow-up. Seventeen men (21-33 years) who reported drinking 27.6 ±6.5 drinks/week with a diagnosis of alcohol abuse/dependence took either kudzu extract (250 mg isoflavones, t.i.d.) or matched placebo on a daily basis. They reported alcohol consumption and desire to use alcohol using a wrist actigraphy device; twice weekly laboratory visits were scheduled to monitor medication adherence and adverse events.
Introduction
Fifty-one percent of adults over the age of 18 and 56 % of those aged 18-44 are current regular drinkers (Schiller et al. 2012) . Thirty percent of current drinkers report drinking excessively (Naimi et al. 2003) and 92 % of US adults who drink excessively report binge drinking in the past 30 days (Town et al. 2006) . Current use was defined as at least one drink in the past 30 days, while binge use includes drinking five or more drinks per day.
Because prescription medications are not universally used or have a perceived modest effect (Krystal et al. 2001; Mark et al. 2003) , providing heavy drinkers with any type of intervention that yields even a modest reduction in drinking is desirable. Furthermore, there is a need to develop efficacious medicines from natural products that have a low incidence of side effects or toxicity (Xu et al. 2005) . The ultimate role that natural preparations play will be complementary and might be useful in treating drug withdrawal and possibly relapse (Lu et al. 2009 ).
One Chinese herbal medicine, XJL (NPI-028), has long been used to reduce the inebriation that results from alcohol consumption. NPI-028 contains the extracts of several plants including Pueraria lobata (kudzu) and Citrus reticulata, which have long been used to lower intoxication (Sun circa 600 AD). It is difficult to speculate on the mechanism of action of kudzu extract, but biochemical studies of the three major isoflavones, puerarin, daidzin, and daidzein, have concluded that they may reduce alcohol consumption by altering either mitochondrial aldehyde dehydrogenase (ALDH2) or monoamine oxidase-acetaldehyde pathways (Keung 2002 (Keung , 2003 . Rooke et al. (2000) have suggested that puerarin may block biogenic amine metabolic pathways, resulting in an alteration in central reward pathways. In our most recent study , we provided evidence that kudzu extract may alter blood ethanol levels after an acute drinking episode. We posited that the observed more rapid increase in blood alcohol levels may result in a faster entry of alcohol to the central nervous system and thus increase either the intensity or duration of the rewarding effects of the first drink, resulting in a delay in the time to a subsequent drink. In fact, we reported that kudzu extract did just that and interrupted binge drinking . Recently, Shen et al. (2012) reported that another flavonoid, dihydromyricetin, reduced alcohol consumption in rats, antagonized the acute effects of alcohol, and counteracted withdrawal signs, and the mechanism was postulated to be due to interactions with the benzodiazepine site on GABA A receptors and increased expression of the GABA A subunit in hippocampus. This profile differs somewhat from that of kudzu extract and may represent a novel herbal compound that may be a therapeutic candidate.
Extracts of the kudzu plant are best known for their ability to suppress alcohol intake or alter alcohol effects by laboratory animals (Benlhabib et al. 2004; Heyman et al. 1996; Keung 2003; Keung and Vallee 1993; Overstreet et al. 1996; Rezvani et al. 2003) . The degree of reduction is often as high as 50 % and the effects appeared within 1 to 2 days of treatment. Puerarin, daidzin, and daidzein are the active isoflavones in kudzu. Regardless of the actual mechanism of action, it is widely accepted that the isoflavones in kudzu are effective in reducing alcohol intake in a number of mammalian species.
We developed a standardized kudzu extract that preserved the ratio of the major isoflavones found in the raw root, except that the concentration of isoflavones was increased to 25 %. We previously demonstrated that a 7-day treatment with this extract significantly reduced alcohol consumption by heavy drinkers in natural and laboratory settings and that this effect is not due to a kudzu-induced increase in alcohol's intoxicating effects ). The present randomized, doubleblind, placebo-controlled study was designed to determine if 4 weeks of treatment with kudzu extract would reduce alcohol consumption in male nontreatment-seeking heavy drinkers in an outpatient setting and to document the safety and side effect profile of this herbal preparation.
Methods

Participants
A total of 21 adult males (17 Caucasian, 1 African American, 2 Hispanic, and 1 Middle Eastern; mean age, 23.8±3.46 years; range, 21-33 years) were recruited through advertisements in local and college newspapers and flyers posted in the Boston area. Because one of the isoflavones in the kudzu plant (daidzein) has weak estrogenic activity in animal models (c.f., Amer et al. 2010 ) and one of the aims of this study was to extend the safety assessments of kudzu extract to a 4-week period, only male subjects were recruited; this restriction was recommended by our local Institutional Review Board (IRB). Persons who responded to these advertisements were given a brief telephone screen and invited to the laboratory for further evaluations. After providing written informed consent, a psychiatric evaluation (Structured Clinical Interview for DSM-IV Disorders; First 2002) was performed and a physical exam including electrocardiogram (ECG), vital signs, full hematology, blood chemistry, and urinalysis tests was conducted. Persons of Asian descent were excluded because of their known increased flushing reaction to alcohol. Individuals with a body mass index (BMI) outside the range of 18-25 kg/m 2 were also excluded. Only individuals who smoked <10 tobacco cigarettes per day, drank <2 cups of coffee per day, smoked <4 marihuana cigarettes per month, and used other illicit drugs <20 times in their life were recruited. Participants could meet the DSM-IV criteria for alcohol abuse or dependence but not dependence on any other drug in the past 3 years. They could not be taking psychotropic medication. Individuals who had maternal alcoholism were also excluded to avoid potential subclinical fetal alcohol syndrome. The demographic profiles of the participants in the two groups are provided in Table 1 ; there were no significant differences among any of these variables (p values ranged between 0.137 and 0.943, df015). The study was approved by the McLean Hospital IRB and individuals were paid for their participation.
Measures
Blood alcohol levels
Estimates of blood alcohol levels were obtained during each study visit using a breathalyzer device (AlcoSensor®, Intoximeter, St. Louis, MO, USA). They were required to come to the laboratory twice a week to provide urine, breath, and blood samples to monitor drug use, alcohol drinking, and liver function, respectively. A total of 227 breath samples were possible from all subject visits during the trial and compliance was equally distributed between the two groups; the kudzu extract group provided 131 of a possible 136 samples and the placebo group provided 84 of a possible 91 samples. Only one breath sample was positive for alcohol during all three phases of the study.
Drinking behavior
Drinking data were collected using a small wristwatch-like device (ActiWatch® Score, Philips/Respironics, Andover, MA, USA) and daily diaries. The ActiWatch has a small button and digital LED faceplate, and participants wore the device 24 h/day for the entire 8-week study and were asked to record all drug and alcohol use by pressing the button to enter the proper code. Participants were provided with a small card that identified unique codes to record the use of alcohol, cigarettes, caffeine, and other drugs. Participants were instructed to report when they consumed each drink, which was defined as a 12-oz can of beer, a 5-oz glass of wine, or a 1.5-oz distilled spirits (97 % reported drinking beer).
In addition, the wrist actigraphy device was programmed to provide an audible "beep" every 3 h±20 min to which the participant was required to enter a number between 0 (no desire) and 10 (greatest desire ever) to record his desire to drink alcohol at that time. The beep was not loud enough to wake the participant from sleep. The ActiWatch® Score device contains an accelerometer that was used to record sleep/ wake activity. We have previously reported on the sleep/wake patterns of the participants in this study (Bracken et al. 2011) .
Participants filled out a daily diary every morning as soon as possible upon awakening. The daily diary was made up of a total of 14 questions of which 9 were Likert-type scales to assess subjective effects on mood, appetite, anxiety, ability to concentrate, irritability, desire to drink alcohol, amount of sleep, physical tension, and physical symptoms in the past 24 h. Three questions asked them to report how many alcoholic drinks, tobacco cigarettes, and caffeinated beverages they consumed and two questions asked about bedtime and wake time.
Participants were assessed with the Beck Depression Inventory (BDI; Beck et al. 1996) and the Beck Anxiety Inventory (BAI; Beck et al. 1988 ) four times during the study: twice during baseline, once at the end of the medication phase (week 6), and once at the end of follow-up (week 8).
Experimental procedure
The study consisted of a 2-week baseline period, 4 weeks of medication (subjects were randomized to either kudzu extract or placebo treatments), and a 2-week follow-up period. Participants recorded their drug use and desire to use alcohol via the wrist actigraphy and daily diaries and reported to the laboratory twice per week for the first 6 weeks and then once per week for weeks 7 and 8 for data collection, urine screening, safety testing, and periodic blood samples to assess puerarin levels using a recent assay that we developed (Ma et al. 2005 ).
Safety, side effects, and adverse event reporting
The safety of kudzu extract was monitored via a number of methods, including twice weekly assessments of vital signs (resting pulse, blood pressure), collecting daily reports of side effects using a daily diary, and twice weekly assessments of adverse events by study staff. An industry standard adverse event reporting form was used to collect information on potential adverse and serious adverse events during each laboratory visit. Side/adverse effects also were tracked on a daily basis by entries in their diaries; items addressed a wide range of somatic complaints. Participants also provided a blood sample during weeks 2 through 8 for laboratory testing, including hematology (white blood cell, red blood cell, platelets, hemoglobin, hematocrit, and mean corpuscular volume), blood chemistry (phosphorus, calcium, cholesterol, triglycerides, and iron), renal function (blood urea nitrogen, uric acid, sodium, and potassium), and liver function (bilirubin [total, direct, and indirect], alkaline phosphatase, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, total protein, albumin, and globulin). In addition, participants were required to have an ECG performed at the screening visit and at the end of treatment and follow-up phases.
Medication adherence assessment
Kudzu extract (Alkontrol-Herbal™; NPI-031; Natural Pharmacia International, Inc., Burlington, MA, USA) was prepared under good laboratory manufacturing procedures. Each 500-mg capsule of kudzu extract contained sugar beet filler and 125 mg of isoflavones (19 % puerarin, 4 % daidzin, and 2 % daidzein). Quality control measures including chemical stability measures were performed on the capsules to verify that activity did not change over the course of the study (Ma et al. 2005) . Participants took two 500-mg capsules, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.) for a total daily dose of 750 mg of isoflavones. Commercially available gelatin capsules (650 mg/capsule, Nature's Bounty®) served as the placebo treatment.
To preserve the double-blind design of the study, kudzu and placebo capsules were repacked into #00 opaque capsules (Apothecary Products, Minneapolis, MN, USA). Morning and evening sets of capsules also contained a 25-mg tablet of riboflavin (vitamin B 2 ) and the afternoon sets contained an additional placebo capsule, in addition to the two kudzu extract capsules, in order to maintain a uniform number (three) of capsules. Capsule sets were individually packaged in small envelopes and marked on the outside with the date and time of day to be consumed. Medication adherence was measured using ultraviolet light to detect riboflavin in centrifuged urine samples (Del Boca et al. 1996) that were collected twice a week. Endogenous levels of riboflavin are too low to fluoresce and participants were instructed to avoid multivitamin complexes while participating in the study. Because riboflavin is cleared from the body quickly, fluorescing urine indicated compliance in the past 18-24 h. In addition, participants reported pill taking by checking time-of-day boxes on daily diaries and by entries on the wrist actigraphy watches.
Urine samples were qualitatively analyzed by high performance liquid chromatography for puerarin levels on a weekly basis starting on the second week of baseline and continuing through the two follow-up visits. Although blood samples were collected from all participants to examine the safety of kudzu, only the last 12 subjects had blood samples collected for the quantitative analysis of puerarin levels.
Data analysis
Data from the ActiWatch device was the primary source for all analyses, while the daily diary served as a backup to verify daily totals and in case of equipment failure. In addition, the diaries permitted the participants to enter additional data that could not be recorded on the watch.
The primary efficacy endpoint was the number of drinks per week and the number of heavy drinking days (five drinks or more) per week. Other measured variables included the percentage of days without drinking and maximal number of consecutive days of no drinking.
Sporadic missing data from the ActiWatches were filled in from the backup daily diary data. Data due to dropouts were handled as missing data, and no values were entered. Missing data points within the treatment weeks in nondropout participants were missing completely at random and so were imputed using multiple regressions. A total of 42 out of 532 data points in the kudzu extract group and 26 out of 357 data points in the placebo group were handled this way, corresponding to 7.9 and 7.3 % of the data, respectively. Separate general linear model analyses of variance (ANOVAs) for data with repeated measurements were used to analyze the number of drinks per week and the number of heavy drinking days per week. The two treatments (kudzu and placebo) were analyzed as fixed effects and time (weeks since randomization) was analyzed as a repeated-measures effect. In all analyses, the baseline drinking level was modeled as a covariate of the respective dependent variable (e.g., the number of drinks per day in the baseline phase was modeled as a covariate when the dependent variable was the number of drinks during the treatment phase). Main effects were followed by Bonferroni post hoc tests. Effect size is reported using the variance-accounted for statistic Partial Eta-Squared (η 2 Partial ). All tests were two-sided, with a significance level of 0.05, and were performed using the SPSS software (version 19.0, IBM SPSS, Inc, Chicago, IL, USA).
Results
Participant flow through the study
Of the 117 individuals who responded to the advertisements and called the laboratory for a telephone screen, 34 were eligible to receive further screening. They were invited to the laboratory and signed informed consent, and the full screening procedure was initiated. Thirteen individuals were either not eligible because of medical reasons, could not be contacted after the screening visit, or declined to participate. A total of 21 individuals were randomized to receive kudzu extract (n011) or placebo (n010). Our a priori target for inclusion for data analysis was completing 3 weeks of treatment-ten and seven participants met these criteria for the kudzu extract/placebo groups, respectively. One placebo-treated subject dropped out of the study during the baseline phase of the study, two more were removed during week 3 due to noncompliance with study procedures (e.g., refused to wear the wrist activity device, fill out daily diaries, etc.), and one dropped out after 4 weeks because of scheduling problems with his job. In the kudzu extract group, one individual withdrew during week 3 and one withdrew at week 5 (both for job-related scheduling issues and not for side effects).
Safety
There were no changes in any vital signs, hematology, blood chemistry, and renal or liver function tests during the three phases of the study. The maximal possible observations were based on the number of side effect categories that were recorded, multiplied by the number of study days in each phase, which was then multiplied by the number of subjects participating in each study phase. The overall incidence of side effects (e.g., headaches, shakes, chills, nausea, etc.) in both groups ranged between 1.7 and 3 %. None of the study participants reported any insomnia, sedation, dizziness, blurred vision, tinnitus, or altered libido.
The BDI and BAI scores remained unchanged during the course of treatment with both kudzu extract and placebo. The BDI for the kudzu extract-treated participants was 1.78±2.11 and 2.63±2.50 at baseline and during treatment, respectively. The BDI measures of the placebo-treated participants were 2.0±2.58 and 1.67±1.37 at baseline and during treatment, respectively. The BAI scores were equally stable and ranged from 0.33 to 1.71 during treatment.
Medication adherence
Subjects were told that they would be removed from the study if they accumulated three riboflavin-negative urine specimens. Of the urine samples collected from the kudzu extract-treated participants (n072), 99 % were positive for riboflavin, while 100 % of the samples from the placebotreated participants (n044) were positive. The number of positive puerarin samples in the kudzu extract treatment group was 98.5 % (n064/65) and 97.2 % (n035/36) for urine and blood samples, respectively. Both negative samples were from the same subject during the first week of kudzu extract treatment; all of his subsequent samples were positive. Finally, participants did not report any missing capsules and did not arrive at the laboratory with extra capsules.
Alcohol consumption-baseline phase The major dependent variable was self-reported alcohol consumption as measured via the wrist actigraphy device. Using the continuous measure of alcohol consumption, drinking was quantified using a number of different variables as noted above. In addition, responses to the audible prompts multiple times a day were used to assess desire to consume alcohol.
During the 2-week baseline phase, the average number of drinks per day was 4.96±1.63 (range, 2-8) for the kudzu extract-treated group and 4.05±2.52 (range, 1-8) for the placebo-treated group; these values were not statistically different (p>0.4).
Alcohol consumption-treatment phase
Figure 1 (top) shows the effects of kudzu extract or placebo treatment on weekly drinking, both as individual data points and as the average. There was an overall main effect for time on number of drinks per week [F(5,75) 0 9.49, p<0.001, η Partial 2 00.388] and there was an interaction for all kudzu extract treatment weeks [F(5,75) 0 2.56, p00.034, η Partial 2 0 0.146]. Both kudzu extract-treated and placebo-treated individuals reduced their drinking somewhat during the first treatment week (Tx1), but these changes were significant only for the kudzu extract-treated group. Significant reductions from baseline drinking continued for the kudzu extract-treated group for treatment weeks 2, 3, and 4. There was a trend towards a significant difference between placebo and kudzu at Tx3 (p00.055). Figure 1 (bottom) shows the effects of treatment on the number of heavy drinking days per week. An overall main effect was observed for both time [F(5,75) 0 3.684, p<0.005, η Partial 2 0 0.197] and for drug [F(1,15) 0 9.428, p00.008, η Partial 2 0 0.386]. There were no significant changes in the placebotreated group, while significant reductions were observed in treatment weeks 1, 3, and 4 for the kudzu extract-treated group. Additionally, there was a significant difference between the two drug treatments during treatment week 4.
The percentage of abstinent days and consecutive days of abstinence are additional ways of assessing alcohol consumption that have been shown to be sensitive outcome measures (Anton et al. 2009; Maisto et al. 2003; O'Malley et al. 2007 ); both of these metrics were differentially affected by kudzu extract. Treatment with kudzu extract increased the percentage of abstinent days by 16 % as compared to placebo [t(14) 0 −2.24, p00.042] (Fig. 2 (left) ). During the baseline phase of the study, both groups averaged a similar number of consecutive days of abstinence with 2.29 ± 0.64 days in the placebo group and 1.80±0.29 days in the kudzu extract group; these were not significantly different. During kudzu extract treatment, the number of consecutive days of abstinence increased to 3.90±0.60 days compared to placebo, which had no effect on this measure (2.14 ± 0.59 days) (Fig. 2 (right) ). This difference between treatments was statistically significant [F(1,14) 0 7.30, p 0 0.017]. It is noteworthy that these participants were daily drinkers and only one of the placebo-treated participants and two of the kudzu extract-treated participants achieved three or more consecutive days of abstinence during the baseline phase. However, during the treatment phase, nine out of ten of the kudzu extract-treated and only three out of seven of the placebo-treated participants achieved three or more consecutive days of abstinence.
Alcohol consumption-follow-up phase Medication was terminated and blinded assessments continued to (1) evaluate any medical issues associated with abrupt termination of treatment and (2) determine whether any treatment-related effects persisted. As depicted in Fig. 1 , both consumption and heavy drinking days during the follow-up week in the kudzu group were significantly different from baseline. The placebo follow-up week was not significantly different from its baseline on either measure. For heavy drinking days, the post hoc analyses from the overall ANOVAs reported above showed that there was a group (placebo vs. kudzu) difference in the follow-up week comparison with the kudzu group being significantly lower than the placebo group.
Desire for alcohol
In spite of observing statistically significant reductions in alcohol consumption, we found no indication that kudzu extract altered the desire for alcohol during any phase of the study. This was evident from a global analysis of the daily Effects of kudzu extract and placebo on the percentage of study days in which participants were abstinent (left) and the number of consecutive days of abstinence (right) from drinking during weeks 3-6 of the study. *p<0.05, significantly different from placebo treatment using baseline drinking as a covariate diary data during all phases of the study. On a 0-to 10-point Likert scale, the participants consistently rated their desire for alcohol in the 4-to 5-point range. For the placebo group, their average craving scores were 4.8±1.5 during the baseline phase, 5.2±1.2 during the treatment phase, and 4.3±2.4 during the follow-up period. For the kudzu extract-treated group, their average craving scores were 5.0±1.1 during the baseline phase, 4.4±1.0 during the treatment phase, and 4.3±0.8 during the follow-up period. There were no significant differences due to medication treatment [F(2,43) 0 0.255, p00.616] or phase [F(1,43) 0 0.974, p00.386], and no interaction between the main factors [F(2,43) 0 0.571, p00.569].
Other effects
Because tobacco and alcohol are so often consumed together, we collected data on cigarette use in order to determine if tobacco intake paralleled the changes in alcohol consumption or, alternatively, if there was a compensatory increase in smoking. As noted in Table 1 , only seven and three subjects in the kudzu extract and placebo treatment groups, respectively, smoked tobacco during the baseline phase of the study (4.59±5.68 cigarettes/day for kudzu extract-treated subjects and 2.55±3.42 cigarettes/day for placebo-treated subjects). During treatment, the number of cigarettes smoked per day decreased to 2.3±3.26 and 2.0±2.07 for the kudzu extract-treated and placebo-treated subjects, respectively. Even though there was a slight reduction in tobacco intake in the kudzu extract-treated individuals, this was not significant based on a fixed effects analysis for drug F(1,48) 0 0.867, p00.356; week F(5,48) 0 0.599, p00.701; or interaction F(5,48) 0 0.091, p00.993. However, the study was not designed to test this hypothesis as individuals were purposely screened for low tobacco intake.
Discussion
The most important finding of the present study was that 4 weeks of treatment with a standardized kudzu extract reduced ad libitum alcohol consumption in a group of nontreatment-seeking heavy drinkers. We previously demonstrated that this kudzu extract significantly reduced alcohol drinking in a group of heavy drinkers during one night of access to a preferred brand of beer in a simulated natural environment ). The present study revealed that kudzu extract is also effective in heavy drinkers in their home, work, and/or school environment. As drinking behavior was measured using a wrist actigraphy device, we were able to monitor alcohol consumption continuously, 24 h/day and 7 days/week. The reductions in drinking during kudzu extract treatment were modest, but were equivalent to a 34-57 % reduction over the treatment weeks; reductions in drinking during placebo treatment ranged from 5.8 to 36 %. The reductions in drinking by kudzu extract were observed by the second week of treatment and persisted through the fourth week of treatment. In addition, the two treatments greatly differed in the percent of days abstinent as well as the number of consecutive days of abstinence. Increase in consecutive days of abstinence is a desirable outcome of an alcohol treatment program, especially during the initial phases of treatment (Washton and Zweben 2006) . The fact that kudzu extract nearly doubled the number of consecutive days that individuals maintained abstinence suggests that it may be a useful adjunct during the early weeks of treatment.
The finding that alcohol intake was reduced without affecting desire to use alcohol at first seemed counterintuitive. However, it is important to recognize that one of the major weaknesses of the measure that we used to record desire to drink alcohol was that it was unidimensional. In reality, drug and alcohol craving is a multifaceted behavior (Potgieter et al. 1999; Singleton and Gorelick 1998) , and while the simplicity of the ActiWatch® Score device certainly helped maintain compliance and clearly offered the participants an opportunity to quickly report on the most basic aspect of their desire to use alcohol in real time, it came at the expense of obtaining a more multidimensional assessment of desire or craving for alcohol. It is quite likely that the desire to use alcohol in an outpatient setting cannot be captured with a single question; we also observed an absence of an effect on desire for alcohol in our previous study .
The rates of alcohol drinking during the follow-up phase were also reduced compared to the baseline phase in both the kudzu extract-treated and placebo-treated groups. We had not expected that any beneficial effects would remain after kudzu extract had cleared the body based on our pharmacokinetic results (Penetar et al. 2006 ). The reduced drinking by both groups during the follow-up phase may have been due to the debriefing protocol that was implemented after treatment ended, as participants were reminded that they met the criteria for heavy alcohol use and that their drinking was discussed and then they were offered a referral for conventional treatment.
A prior study of kudzu to treat alcohol use in an outpatient setting reported that kudzu had no effect on maintaining sobriety or altering alcohol craving (Shebek and Rindone 2000) . However, these authors noted that there was a large dropout rate, subjects were not supervised while they completed the questionnaires, and there was only a single assessment each month. In addition, there were no measures of compliance collected and no information on the origin, quality, or content of the kudzu preparation provided (we analyzed a variety of commercial preparations and found them to vary widely in their isoflavone concentration from 0 to 50 % of claimed amounts). All of the above factors may have contributed to the negative findings of this study.
We employed two different biochemical methods (urinary riboflavin and plasma puerarin levels) to monitor medication adherence. The lack of side effects after 4 weeks of treatment with both placebo and kudzu extract is likely one of the major reasons for the high rate of medication adherence. Vital signs, measures of blood chemistry, liver function tests, and urinalysis assessments were all normal. One animal study in particular demonstrated that kudzu extract and its major components are very safe, even after relatively large doses (2 g/day) over a 3-month treatment period (Keyler et al. 2002) .
It is important to place the magnitude of the effects of kudzu extract on alcohol drinking in context. Alcohol drinking was not completely eliminated by kudzu extract in the present study, but was reduced from baseline drinking by an average of 45 % over the 4 weeks of treatment. From a harm reduction perspective, kudzu extract results in a desirable outcome for a population of heavy drinkers, especially when one considers the other important finding of the present study-kudzu extract was without any adverse events and minimal side effects. We recently demonstrated that kudzu extract does not potentiate the intoxicating effects of alcohol ) and does not interfere with sleep/wake activity (Bracken et al. 2011) . These findings, coupled with the present report, support the notion that kudzu extract might be useful as an adjunct to a comprehensive treatment program and combined with other medications such that the dose of the other (stronger) medication might be lowered and thus reduce the incidence of side effects. In addition, this was not a treatment clinical trial, so the effects on alcohol intake might have been more robust in treatmentseeking individuals.
The limitations of this study include (1) a relatively small sample size; (2) short (4-week) treatment interval; (3) only young male beer drinkers were included; (4) only visual inspection of the fluorescence for riboflavin was performed; (5) the three times a day dosing interval may not be optimal; and (6) a unidimensional metric of "desire for alcohol" was used. Despite these limitations, statistical significance was observed in a number of primary measures of drinking, and because the participants were not seeking treatment, a longer treatment protocol would have had many more dropouts. Future studies are planned to include older subjects who have been drinking longer, both male and female individuals who are actively seeking treatment, and a spectrophotometer will be used to quantify riboflavin levels and a more comprehensive method of assessing "craving" will be used.
In conclusion, the results of the present study demonstrate that 4 weeks of treatment with a kudzu extract results in modest reductions in alcohol consumption among heavy drinkers who are not seeking treatment. The advantages of kudzu over other medications may be that (1) the public is embracing the role that complementary/alternative or nutraceutical products play in managing health, so there is a clear interest in trying novel therapies; (2) the low incidence of side effects helps to maintain medication adherence; and (3) kudzu extract appears to work rather quickly (within 2-3 weeks), so the likelihood that a person might "give up" because the medication "is not working" may be reduced. Additional research is clearly warranted to determine exactly how this preparation might fit into current alcohol treatment programs.
